Company intelligence / Profile preview
Invea Therapeutics
Guilford, CT, United Statesinveatx.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Invea’s lead asset INVA8001 is a highly selective chymase inhibitor targeting mast cell-driven inflammation in IMIDs such as atopic dermatitis and chronic urticaria. The compound was previously evaluated by Daiichi Sankyo in a Phase 2 trial that did not meet its primary endpoint; Invea plans a redesigned Phase 2b trial addressing prior limitations. Their second candidate, INVA8003, targets ASC for multi-inflammasome inhibition and is in preclinical development. No approved products yet[5].
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Daiichi Sankyo Company (in-license of lead asset)[5]
Beyond the preview
Go deeper on Invea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invea Therapeutics.